Merger Update: Watson, Actavis
The settlement of an antitrust action has put the acquisition of Actavis Inc. by Watson Pharmaceuticals back on track with a $5.9 billion price tag. According to the complaint filed with...
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: